Digital AI in Drug Discovery: Day One There is no denying that artificial intelligence (AI) has captured the imagination of innovators working across the pharmaceutical sector.
News Pfizer’s new cancer unit sees eight new blockbusters by 2030 Fresh from the $43 billion acquisition of antibody-drug conjugate (ADC) specialist Seagen, Pfizer has laid out plans for its dedicated oncology division in front of invest
Events Partner Content 2nd RNA Targeted Drug Discovery Summit At a time when the previously untapped drug discovery opportunity promised within RNA opens up, the
Partner Content Partner Content Less than 3 weeks to SMi's 3rd Annual Drug Discovery Chemist... 3 weeks to SMi's 3rd Annual Drug Discovery Chemistry
Partner Content Partner Content Exclusive insights into the latest innovations at Drug Disco... Exclusive insights into the latest innovations
News Pulmonary fibrosis drug developer Avalyn files IPO Avalyn Pharma hops on the IPO train, filing to list on the Nasdaq and raise funds for late-stage trials of its inhaled pulmonary fibrosis therapies.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
